Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab
Crossref DOI link: https://doi.org/10.1007/s40265-017-0794-1
Published Online: 2017-08-02
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Torres, Tiago
License valid from 2017-08-02